Two Sigma Securities LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 77.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,977 shares of the company’s stock after buying an additional 3,922 shares during the period. Two Sigma Securities LLC’s holdings in Eli Lilly and were worth $755,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. Prospera Financial Services Inc increased its position in Eli Lilly and by 6.7% in the first quarter. Prospera Financial Services Inc now owns 14,258 shares of the company’s stock valued at $1,208,000 after buying an additional 895 shares during the last quarter. Alpha Windward LLC increased its position in Eli Lilly and by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock valued at $189,000 after buying an additional 44 shares during the last quarter. Private Trust Co. NA increased its position in Eli Lilly and by 43.5% in the first quarter. Private Trust Co. NA now owns 7,787 shares of the company’s stock valued at $654,000 after buying an additional 2,360 shares during the last quarter. Verde Servicos Internacionais S.A. acquired a new position in Eli Lilly and during the first quarter valued at $10,598,000. Finally, TNB Financial acquired a new position in Eli Lilly and during the first quarter valued at $430,000. Institutional investors and hedge funds own 75.61% of the company’s stock.

Eli Lilly and Company (NYSE:LLY) traded up 0.02% during mid-day trading on Friday, reaching $81.55. The company had a trading volume of 799,858 shares. The stock has a 50 day moving average of $83.00 and a 200 day moving average of $81.69. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72. The stock has a market capitalization of $86.04 billion, a price-to-earnings ratio of 35.29 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the prior year, the company posted $0.86 EPS. The company’s quarterly revenue was up 7.8% on a year-over-year basis. Analysts anticipate that Eli Lilly and Company will post $4.16 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.54%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

COPYRIGHT VIOLATION WARNING: “Eli Lilly and Company (NYSE:LLY) Stake Boosted by Two Sigma Securities LLC” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/11/eli-lilly-and-company-nyselly-stake-boosted-by-two-sigma-securities-llc.html.

Several research firms have weighed in on LLY. Piper Jaffray Companies restated a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a research note on Monday, April 17th. Cowen and Company upped their price target on Eli Lilly and from $85.00 to $95.00 and gave the stock an “outperform” rating in a research note on Monday, April 17th. Morgan Stanley downgraded Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 price target for the company. in a research note on Monday, April 17th. BMO Capital Markets downgraded Eli Lilly and from a “market perform” rating to an “underperform” rating and dropped their price target for the stock from $73.00 to $71.00 in a research note on Monday, April 17th. Finally, Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research note on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $88.27.

In related news, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the sale, the vice president now owns 62,056 shares in the company, valued at approximately $4,962,618.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Melissa S. Barnes sold 1,900 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the sale, the insider now owns 14,041 shares in the company, valued at approximately $1,134,231.98. The disclosure for this sale can be found here. In the last ninety days, insiders sold 669,733 shares of company stock worth $55,845,287. Corporate insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.